| Fiscal period | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Period End Date | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 |
|---|
| Sales | 4,373.40 | 4,655.60 | 4,451.60 | 4,138.70 | 5,063.30 | 4,837.40 | 4,731.70 | 4,946.20 | 5,280.60 | 2,769.50 |
| Total Revenues | 4,373.40 | 4,655.60 | 4,451.60 | 4,138.70 | 5,063.30 | 4,837.40 | -- | 4,946.20 | 5,280.60 | 2,769.50 |
| Cost of sales | 2,830.70 | 2,975.20 | 2,996.20 | 2,722.50 | 3,248.10 | 3,064.10 | 2,900.20 | 2,966.70 | 3,228.80 | 1,661.40 |
| PPA product discontinuation | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross Profit | 1,542.70 | 1,680.40 | 1,455.40 | 1,416.20 | 1,815.20 | 1,773.30 | 1,831.50 | 1,979.50 | 2,051.80 | 1,108.10 |
| Goodwill impairment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Research and development | 112.20 | 122.50 | 123.10 | 122.00 | 177.70 | 187.40 | 218.60 | 167.70 | 184.00 | 88.20 |
| Write-off of in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling and administration | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling | 546.60 | 641.80 | 584.80 | 536.40 | 579.10 | 567.00 | 595.70 | 598.40 | 665.00 | 325.90 |
| Distribution | 98.00 | 110.50 | 113.00 | 93.00 | 100.40 | 96.10 | 94.20 | 87.00 | 88.30 | 47.90 |
| Administration | 468.00 | 522.30 | 512.30 | 482.00 | 496.00 | 503.00 | 435.90 | 461.10 | 452.20 | 309.10 |
| Restructuring | 110.10 | 42.20 | 42.50 | 16.90 | 3.50 | 26.30 | 21.00 | 61.00 | 31.00 | 26.90 |
| Impairment charges | (88.90) | (90.00) | 0.00 | (173.10) | (346.80) | (184.50) | (224.40) | (47.50) | (2,631.00) | (215.60) |
| Other operating income | (6.00) | 0.80 | (0.80) | 417.60 | 3.70 | (4.20) | (5.20) | 41.40 | -- | -- |
| Total Operating Expenses | 1,429.80 | 1,528.50 | 1,376.50 | 1,005.80 | 1,699.80 | 1,568.50 | 1,595.00 | 1,381.30 | 4,051.50 | 1,013.60 |
| Operating Income (Loss) | 112.90 | 151.90 | 78.90 | 410.40 | 115.40 | 204.80 | 236.50 | 598.20 | (1,999.70) | 94.50 |
| Interest, net | 187.80 | 173.80 | 156.00 | 125.00 | 131.20 | 121.70 | 128.00 | 168.10 | 216.60 | 89.90 |
| Write-off of in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Investment impairment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Unusual litigation | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain (loss) on sale of investment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other income (loss) net | 0.90 | 10.40 | (53.10) | (26.70) | (17.20) | 66.00 | (6.10) | 10.10 | (22.70) | (26.90) |
| Gain (loss) on extinguishment of debt | (6.70) | 3.20 | (8.90) | -- | (20.00) | (0.20) | (0.50) | (135.20) | (1.10) | (0.90) |
| Tysabri®royalty stream - change in fair value | -- | -- | 0.00 | -- | (96.40) | 22.10 | 188.70 | (24.90) | (2,608.20) | -- |
| Income (loss) before income taxes | (80.70) | (8.30) | (139.10) | 258.70 | (149.40) | 171.00 | 290.60 | 280.10 | (4,848.30) | (23.20) |
| Pre-tax income: U.S | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Pre-tax income: Foreign | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Current- Foreign | 57.00 | 56.60 | 30.80 | 81.30 | 47.40 | 16.10 | 75.10 | 46.10 | 26.70 | 40.40 |
| Current: Federal | -- | -- | -- | -- | -- | (2.20) | 22.70 | 96.40 | 93.00 | 59.20 |
| Current: State | 30.40 | 18.20 | (7.80) | 14.90 | 17.60 | 51.00 | 66.40 | 4.00 | 0.70 | 3.20 |
| Deferred | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Deferred: Federal | -- | -- | -- | -- | (0.10) | 0.00 | (13.90) | 6.80 | (7.60) | (32.50) |
| Deferred: State | 27.60 | (12.90) | (8.60) | 3.30 | (52.30) | (30.20) | 7.30 | 1.00 | (5.10) | (3.30) |
| Deferred: Foreign | (37.30) | (68.00) | (26.10) | (13.90) | (2.10) | (9.80) | 2.00 | 1.20 | (394.10) | (69.50) |
| Income tax expense (benefit) | 80.00 | (3.90) | (8.20) | 389.60 | 13.20 | 24.90 | 159.60 | 160.50 | (835.50) | (28.80) |
| Current:Ireland | 2.30 | 2.00 | 2.80 | 303.60 | 2.70 | -- | 22.70 | (8.10) | -- | 1.40 |
| Deferred (credit):Ireland | -- | 0.20 | 0.70 | 0.40 | (0.10) | -- | (13.90) | 13.10 | -- | (27.70) |
| Income (loss) from Continuing Operations | (160.70) | (4.40) | (130.90) | (130.90) | -- | -- | -- | -- | -- | -- |
| Income (loss) from Discontinued Operations, net of tax | (11.10) | (8.30) | (9.70) | 62.00 | -- | -- | -- | -- | -- | -- |
| Net income attributable to common shareholders | (171.80) | (12.70) | (140.60) | (68.90) | (162.60) | 146.10 | 131.00 | 119.60 | (4,012.80) | 5.60 |
| Earnings Per Share (Basic) - Cont Ops | (1.17) | (0.03) | (0.97) | (0.98) | -- | -- | -- | -- | -- | -- |
| EPS (Basic) : Disc Ops | (0.08) | (0.06) | (0.07) | 0.46 | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Basic) | (1.25) | (0.09) | (1.04) | (0.52) | (1.19) | 1.07 | 0.95 | 0.84 | (28.01) | 0.04 |
| Earnings Per Share (Diluted) - Cont Ops | (1.17) | (0.03) | (0.97) | (0.98) | -- | -- | -- | -- | -- | -- |
| Earnings Per Share (Diluted) - Disc Ops | (0.08) | (0.06) | (0.07) | 0.46 | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Diluted) | (1.25) | (0.09) | (1.04) | (0.52) | (1.19) | 1.07 | 0.95 | 0.84 | (28.01) | 0.04 |
| Weighted Average Shares Outstanding (Basic) | 137.40 | 135.30 | 134.50 | 133.60 | 136.10 | 136.00 | 137.80 | 142.30 | 143.30 | 145.60 |
| Weighted Average Shares Outstanding (Diluted) | 137.40 | 135.30 | 134.50 | 133.60 | 136.10 | 136.50 | 138.30 | 142.60 | 143.30 | 146.10 |